News & Analysis as of August 21, 2025

Drug Pricing

+ Follow

A repository for the most well-read content on JD Supra at any given time, along with occasional roundups of popular content by specific topic. Also stop by for monthly recaps of hot articles for the previous... more +

Update on biosimilars in Canada – June 2025

Smart & Biggar on 6/25/2025

This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access—since our March 2024 update. Consultation on revised biosimilar...more

The Trifecta: What to Expect from a Second Trump Administration and a Republican Congress

King & Spalding on 12/11/2024

Republicans have swept the 2024 elections, returning Donald Trump to the White House as the 47th President and flipping the Senate to a Republican majority. Having narrowly maintained control of the House of Representatives,...more

Update on biosimilars in Canada – August 2020

Smart & Biggar on 8/27/2020

The following provides an overview of the many developments regarding biosimilars in Canada (approvals, pending submissions, regulatory, litigation and market access) that have taken place since our last update in October...more

FDA Issues Proposed Rule and Draft Guidance on Drug Importation

King & Spalding on 1/7/2020

In late December 2019, the Food and Drug Administration (FDA), an agency operating within the Department of Health and Human Services (HHS), issued two documents—a Proposed Rule and a Draft Guidance—intended to establish two...more

4 Results

View per page

Page: of 1

Today's Popular Updates › Canada › Drug Pricing

Update on biosimilars in Canada – June 2025

The Trifecta: What to Expect from a Second Trump Administration and a Republican Congress

Update on biosimilars in Canada – August 2020

FDA Issues Proposed Rule and Draft Guidance on Drug Importation

"My best business intelligence, in one easy email…"